Investor Library

StemRIMIR Library

All Timely Disclosure Information Financial Results Presentation Materials IR News

November 11, 2026	Timely Disclosure Information	StemRIM Announces Issuance of New Shares as Remuneration for Restricted Stock
November 9, 2026	Timely Disclosure Information	Patent Registration (Australia) for Redasemtide in Fatty Liver and NASH
November 9, 2026	Timely Disclosure Information	Patent Registration (Israel) for Redasemtide in Cartilage Disorders
October 30, 2026	Timely Disclosure Information	Presentation Material for Business Plan and Growth Potential
October 7, 2026	Timely Disclosure Information	Notice Regarding US Patent Registration of SR-GT1 for Dystrophic Epidermolysis Bullosa
September 25, 2026	Timely Disclosure Information	Proposal for Approval of Issuance of Stock Options to our Company’s Executive Officers, Employees, and External Collaborators
September 25, 2026	Timely Disclosure Information	Nomination of Director Candidates, Audit & Supervisory Board Member and Substitute Audit & Supervisory Board Member Candidates
September 25, 2026	Timely Disclosure Information	Patent Registration in South Korea for Redasemtide in Cartilage Disorders
September 10, 2026	Timely Disclosure Information	StemRIM Announces Fixed Details of the Issuance of Stock Options to Directors
September 10, 2026	Timely Disclosure Information	StemRIM Announces Fixed Details of the Issuance of Stock Options to Employees
September 9, 2026	Timely Disclosure Information	Non-consolidated Financial Results for the Fiscal Year Ended July 31, 2026 [Japanese GAAP]
September 9, 2026	Timely Disclosure Information	StemRIM Announces Issuance of Stock Acquisition Rights as Stock Options to Directors
September 9, 2026	Timely Disclosure Information	StemRIM Announces Issuance of Stock Acquisition Rights as Stock Options to Employees
August 3, 2026	Timely Disclosure Information	StemRIM Announces Patent Registration for SR-GT1 Aimed at Curative Treatment of Dystrophic Epidermolysis Bullosa in South Korea
July 22, 2026	Timely Disclosure Information	StemRIM Announces Patent Registration (Mexico) for Redasemtide, as an Additional Therapeutic Indication of Cartilage Disorders